Fortress Biotech Inc (FBIO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Lindsay A. Rosenwald
Employees:
170
1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS, FL, 33154
781-652-4500

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also develops late stage product candidates such as intravenous Tramadol for the treatment of post-operative acute pain.

Data derived from most recent annual or quarterly report
Market Cap 415.232 Million Shares Outstanding133.087 Million Avg 30-day Volume 1.363 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.24
Price to Revenue0.9705 Debt to Equity-3.467 EBITDA-192.707 Million
Price to Book Value3.2888 Operating Margin-341.7629 Enterprise Value-5.083 Million
Current Ratio0.992 EPS Growth-1.056 Quick Ratio0.739
1 Yr BETA 5.3487 52-week High/Low 17.4 / 1.24 Profit Margin-358.682
Operating Cash Flow Growth-12.7472 Free Cash Flow to Firm (FCFF) TTM -117.838 Million Free Cash Flow to Equity (FCFE) TTM49.001 Million
Altman Z-Score-8.4916
View SEC Filings from FBIO instead.

View recent insider trading info

Fortress Biotech Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding FBIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FBIO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-02-14 by WEISS MICHAEL S
  • 4: filed on 2022-12-19 by LU LUCY
  • 3: filed on 2022-12-19 by LU LUCY
  • 4: filed on 2022-12-05 by ROSENWALD LINDSAY A MD
  • 4: filed on 2022-12-02 by ROSENWALD LINDSAY A MD
  • 4: filed on 2022-12-02 by JIN DAVID
  • 4: filed on 2022-10-28 by JIN DAVID
  • 4: filed on 2022-10-24 by ROSENWALD LINDSAY A MD
  • 3: filed on 2022-08-25 by JIN DAVID
  • 4: filed on 2022-04-29 by KLEIN DOV

    • Events (8k)

  • 8-K: filed on 2023-11-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-11-14:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-26:
    Item 8.01: Other Events
  • 8-K: filed on 2023-10-10:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-05:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-04-13:
    Item 5.07: Submission of Matters to a Vote of Security Holders

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    3.4 Million total shares from 4 transactions

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ROSENWALD LINDSAY A MD PRESIDENT, CEO & CHAIRMAN

    • Officer
    • Director
    • 10% Owner
    		 2,597,440 2023-11-14 5

    WEISS MICHAEL S SEE REMARKS

    • Officer
    • Director
    		 1,130,520 2023-11-14 3

    LOBELL J JAY

    • Director
    		 1,635,401 2023-02-10 2

    ROWINSKY ERIC K

    • Director
    		 931,976 2023-02-10 2

    LU LUCY

    • Director
    		 133,379 2023-02-10 4

    JIN DAVID CHIEF FINANCIAL OFFICER

    • Officer
    		 1,438,757 2023-02-10 1

    HOENLEIN MALCOLM

    • Director
    		 535,636 2023-01-01 1

    HARVEY JIMMIE

    • Director
    		 950,000 2023-01-01 1

    KLEIN DOV

    • Director
    		 851,015 2023-01-01 1

    LORENZ KEVIN

    • Director
    		 324,572 2023-01-01 1

    HUNTER ROBYN CHIEF FINANCIAL OFFICER

    • Officer
    		 163,877 2021-09-21 0

    AVGERINOS GEORGE SVP, BIOLOGICS OPERATIONS

    • Officer
    		 255,170 2018-12-11 0

    BEERMAN NOAH D SEE REMARKS

    • Officer
    		 0 2011-09-26 0

    COOPER GLENN L MD SEE GENERAL REMARKS

    • Officer
    • Director
    		 0 2011-09-13 0

    SANDAGE BOBBY W PHD PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2011-09-13 0

    RITTER DALE SEE GENERAL REMARKS

    • Officer
    		 0 2011-09-13 0

    ROGERS MICHAEL W

    • Director
    		 0 2011-09-13 0

    BARRETT DAVID JONATHAN

    • Director
    		 0 2011-09-13 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    WEISS MICHAEL S - Director - Officer SEE REMARKS

    		2023-11-16 17:46:56 -0500 2023-11-14 P 147,058 $1.70 a 1,130,520 direct 33.9713 2.3923 33.9713 2 0.0 1

    WEISS MICHAEL S - Director - Officer SEE REMARKS

    		2023-11-16 17:46:56 -0500 2023-11-14 P 147,058 a 147,058 direct

    ROSENWALD LINDSAY A MD - Director - Officer - > 10% Owner PRESIDENT, CEO & CHAIRMAN

    		2023-11-16 17:50:28 -0500 2023-11-14 P 1,567,515 $1.70 a 2,597,440 direct 33.9713 2.3923 33.9713 2 0.0 1

    ROSENWALD LINDSAY A MD - Director - Officer - > 10% Owner PRESIDENT, CEO & CHAIRMAN

    		2023-11-16 17:50:28 -0500 2023-11-14 P 1,567,515 a 1,567,515 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    FORTRESS BIOTECH INC FBIO 2023-12-08 22:15:04 UTC 1.3206 3.9994 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 21:45:04 UTC 1.3206 3.9994 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 21:15:04 UTC 1.3206 3.9994 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 20:45:04 UTC 1.3206 3.9994 350000
    FORTRESS BIOTECH INC FBIO 2023-12-08 20:15:07 UTC 1.3523 3.9677 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 19:45:04 UTC 1.3523 3.9677 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 19:15:03 UTC 1.3523 3.9677 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 18:45:03 UTC 1.3523 3.9677 350000
    FORTRESS BIOTECH INC FBIO 2023-12-08 18:15:04 UTC 1.3523 3.9677 350000
    FORTRESS BIOTECH INC FBIO 2023-12-08 17:45:03 UTC 1.1568 4.1632 350000
    FORTRESS BIOTECH INC FBIO 2023-12-08 17:15:03 UTC 1.1568 4.1632 350000
    FORTRESS BIOTECH INC FBIO 2023-12-08 16:45:05 UTC 1.1568 4.1632 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 16:15:04 UTC 1.1568 4.1632 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 15:45:04 UTC 0.6931 4.6269 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 15:15:04 UTC 0.6931 4.6269 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 14:45:04 UTC 0.6862 4.6338 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 14:15:03 UTC 0.6862 4.6338 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 13:45:03 UTC 0.8467 4.4733 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 13:15:04 UTC 0.8467 4.4733 400000
    FORTRESS BIOTECH INC FBIO 2023-12-08 12:45:05 UTC 0.8467 4.4733 400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund FBIO -4200.0 shares, $-1219.26 2023-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments